SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GenVec - GNVC
GNVC 7.1930.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Savant who wrote (97)1/17/2017 9:45:24 PM
From: Gary Mohilner1 Recommendation

Recommended By
Savant

  Read Replies (1) of 106
 
Here's a link to the Presentation that's being made tomorrow:

content.equisolve.net

Their is a lot of new content and seems to be a new emphasis on hemophilia. I don't know if they're close to having something in the clinic for it, or perhaps are near gaining funding through either partnership or grant, but it's clearly being emphasized.

I believe that the science is solid at GNVC, but finance is their weak suit, at least currently. While the reverse split makes the share count minuscule, I would hope that substantial dilution wouldn't occur until the share price has reached double digits at the minimum.

One or more partnerships would be the most positive thing the company could do for shareholders, that would answer funding questions and assure that they have the wherewithal to carry drug trials to conclusion. Of course if Merial suddenly put the FMD vaccine on the market, GNVC could see unexpected funds routinely and it might answer financial concerns.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News